Sign the Resolution for a Federal Commission on Drug Policy
Contents | Feedback | Search | DRCNet Home Page | Join DRCNet
DRCNet Library | Schaffer Library | Major Studies
Marihuana, A Signal of Misunderstanding
National Commission on Marihuana and Drug Abuse
Proving a causal relationship between the use of any substance and an associated illness or condition is extremely difficult. Ideally, prospective longitudinal studies on large populations of both substance users and nonusers matched for socioeconomic and psycho-cultural variables should be performed for many years in order to detect subtle or cumulative effects. Unfortunately, the enormous expenditures of research effort and finances that would be required for a large scale investigation of this nature are prohibitive.
Consequently, carefully designed and controlled, clinical and epidemiological studies
of very heavy, very long-term cannabis users in foreign countries must be relied upon to
provide important data on possible effects because these populations are not obtainable in
the United States.
Preliminary results (Freedman and Fink 1971, Fink and Dornbush 1971, Fink 1971) from an intensive medical, neurological, and psychiatric study of 31 male chronic hashish users in Greece, performed under contract to the National Institute of Mental Health, have revealed few abnormalities in these individuals. Non-users matched for socioeconomic, and psycho-cultural factors including life style, alcohol and tobacco consumption and nutrition and general health have not been studied.
In collaboration with Professors Miras and Stefanis in Athens, Fink and co-workers are studying a population of chronic hashish users that Professor Miras has known for many years. The population studied is composed of 31 male subjects ranging in age from 26 to 69 years with a mean of 46 years.
The subjects report starting hashish use at 13 to 35 years of age with a mean of 19. They have -used hashish from 10 to 49 years, with a median of 28 years. In the past they used an average of eight grams of hashish daily with a range of 2 to 24: grams daily. (The hashish it estimated to contain 4% THC on the average. Therefore, average daily use was 320 mg. of THC).
In the past, 27 of the subjects were daily -users and four used every other day. Frequently of hashish use per day was: once per day-2 subjects, twice per day-6 subjects, three times per day-14 subjects, four times per day-4 subjects, and five, or more times per day-5 subjects.
The men reported a reduction in drug use with time ascribed to increasing difficulty in obtaining adequate supplies due to increased enforcement of the drug regulations. At present they use an average of three grams of hashish daily (320 mg. of THC) with a range of one to 10 grams daily.
Twelve now use hashish daily, eight use, every other day and 11 use less frequently. Frequency of daily hashish use is: once per day-5 subjects, twice per day-12 subjects, three times per day-10 subjects, four times per day-2 subjects, and gve(sic) or more times per day-2 subjects.
The men are primarily hashish users. One has used opiates. Two are heavy users of alcohol and six report occasional to frequent use of alcohol at the present time. Tobacco is smoked by all subjects averaging 40 cigarettes per day.
Twenty-three of the subjects report periods of abstinence from hashish averaging ten months but up to three years. Hashish use is primarily social by 20 subjects, and 15 subjects smoke in solitude.
Pipes and cigarettes in which hashish is mixed with tobacco are used interchangeably. The usual time of smoking is after work (21 subjects) but 12 subjects smoke before work and five smoke anytime.
In this population, the median education is three-and-a-half years of school with a range of none to nine. Five of the men are illiterate. Twenty-one of the men are married, one is cohabiting, four are single and five are divorced or separated.
All of the married men are employed and support their families. The subjects report changing their jobs frequently and 11 had periods of unemployment from three to 120 months. Ten were classified as skilled workers and 21 as unskilled workers. Their jobs include selling scrap metals, general labor, cartage, messenger, maintenance assistants, etc.
Arrests are common and 19 report at least one non-hashish related arrest. Eighteen have been in regular military service, six were exempt because of hashish use and seven for other reasons.
Interestingly, 10 of the 15 wives interviewed prefer the behavior and attitudes of their husbands when they are using hashish compared to when they are drug-free.
In regard to family and personal background 20 had refugee parents, 13 had alcoholic or hashish using fathers, 26 had three or more siblings, 19 had dominant mothers. Fifteen of 21 had dominant wives. Seven reported broken homes under age 16.
Apparently, the subjects participation in society is consistent with their lower socioeconomic background. No gross behavioral deviation was detected I in this population.
Psychiatric status was evaluated by history and psychiatric interview. Nine have had psychiatric hospitalization of which three were in the military and related to hashish use. Two have, had psychiatric outpatient treatment. Eight had histories of neurotic traits during childhood. In their psychiatric evaluation, three men are considered to have psychiatric pathology. Two of these were considered sociopaths on the basis of homosexuality and criminal behavior. The third was diagnosed as a schizophrenic. No overt signs of any organic mental syndrome were detected. None of the three men were believed to require psychiatric intervention. The schizophrenic, although suspicious and withdrawal, is a successful business man and lives with his family on weekends.
Complete physical and neurological examination revealed three prominent findings. All had very poor dentition which the men ascribed to hashish smoking. Chronic bronchitis was detected in 14 of the men and emphysema in three others. This finding is not surprising because all subjects were tobacco cigarette smokers averaging 40 cigarettes per day, in addition to their very heavy hashish consumption. Enlarged livers were also found in nine of the 31 subjects.
Because no extensive psychological test battery has been developed or standardized in Greece, American tests were used. These tests are not culture-free, and it is possible that certain items or subtests were inappropriate for the subjects because they had not acquired the type of knowledge or skills required due to their poor level of education.
The Wechsler-Bellevue I.Q. tests were translated into Greek and administered. Because of these, factors, comparison of level of performance between these subjects and white middle class Americans is meaningless.
The mean I.Q. is 86 with a range of 69 to 109. The mean verbal is 90.3 and the mean performance was 83.6. The group of subjects performed lower than expected on digit symbol, digit span and similarities but higher than expected on comprehension, arithmetic, vocabulary and picture completion. The Ravens Progression Matrices showed a similar pattern and mean I.Q. The significance of these findings will depend on a comparison with a matched nonuser population.
Resting electroencephalograms were obtained in 30 subjects and evaluated independently by four experts. Twenty-five were within normal limits.
Testing was incomplete in one record. One record in a subject who had a head injury within the prior three months showed focal slowing.
Two of the four experts judged the remaining three, records as showing low degrees of average to low voltage theta activity indicative of cerebral dysfunction. The remaining two experts judged these records as within normal limits.
This medical and psychological data suggests some effects of very long term, very heavy hashish use. Without a matched comparison group, factors independent of hashish use, such as age, socioeconomic conditions, or environmental conditions, may account for the observed changes.
However, the researchers note that these men have survived chronic hashish use in high
doses without gross behavioral deviation.
Another foreign investigation (Ruben et al., 1972) conducted in Jamaica (under contract for the National Institute of Mental Health) studied chronic cannabis users and matched nonuser controls. Preliminary findings have shown little evidence of significant differences between the two groups in the extensive anthropological, medical, psychiatric and psychological investigations.
Ganja use is widespread and endemic in the Jamaican lowest socioeconomic strata, and in particular in a millenial-religious sect known as the Rastafarians. More than 50% of all male Jamaicans are estimated to use some form of cannabis, and probably about 20% are regular heavy users of ganja.
The drug was brought to Jamaica from India over 130 years ago by indentured East Indian laborers. However, presently the heaviest ganja users are Afro-Jamaicans who comprise 90% of the population.
The Rastafarian religious sect, founded by Marcus Garvey, preach a "Back to Africa" destiny and claim Haile Selassie to be God. The Rastafarians have always worn. long hair and beards and dressed eccentrically. They believe that "the herb" was given them by God to help them to understand his wisdom exemplified in their greeting, "Peace and Love."
The Rastas reject the values of the dominant society and regard the government as "the powers of Babylon". They have, chosen to opt out of conventional society and instead work and live in a communal existence in poverty. They emphasize the value of ganja in achieving a new level of meaning in this existence.
The Rastafarians add ganja to their infant first bath and start feeding the drug to their infants from the time of weaning in an infusion known as ganja tea. They continue to smoke and drink the drug throughout life.
They, like many other Jamaicans, believe in its medicinal properties especially for asthma and indigestion and promotion of healing; that it gives protection from evil spirits; that it cleanses the skin and purifies the blood; that it promotes sexual vigor; that it gives energy for work and relieves fatigue and provides relaxation after work.
Extensive in-depth studies have been carried out by a team of anthropologists from The Research Institute for the Study of Man in conjunction with The Departments of Psychiatry, Pathology, Physiology and Medicine, of the University of the West Indies. Anthropology field workers lived for extensive periods of time in five rural communities (including fishing, farming and cane cutting areas) and two urban districts.
Over 2,000 people were observed and studied in these communities. Overall life styles of the ganja users were not notably different from nonusing individuals in the Jamaican lowest socioeconomic strata. Users are working, maintaining stable families and homes, and actively participating in their society. No evidence was noted of crime or aggressive behavior or drug use other than alcohol related to ganja use. No evidence of physical dependence was demonstrated. Minimal psychological dependence was observed but no drug craving was expressed.
Thirty long-term ganja smokers and 30 nonusers matched demographically to control factors other than ganja use, were chosen as representative of this functioning lower socioeconomic population and selected for intensive hospital study in order to determine, differences between the two groups.
The mean age of the subjects was 33 with a range of 23 to 51. The primary occupation of one-third of the subjects was farming. The next most common occupations were, fishing, skilled and semiskilled laborers. Half practiced no formal religion, five were Rastafarians and the remainder practiced a wide variety of traditional religious. Almost three-fourths of the males had stable "marriages" and the remaining single subjects were predominantly the younger ones.
The subjects were divided into three groups. Twenty-three were nonganja smokers, 28 were regular daily ganja smokers and 9 were occasional ganja smokers using the drug several times a we or less. Three types of regular ganja smokers were delineated: light smokers using one to four spliffs daily moderate smokers using four to seven spliffs daily; and heavy smokers using eight or more spliffs per day.
Age of first use ranged from 8-36 years of age. Regular use of ganja occurred at a median age of 16 years with a range of 9-25 years. All ganja smokers had used the drug at least 7 years and some up to 37 years with a mean of 17.5 years.
The ganja users consumer on the average seven spliffs of ganja daily with a range of one to 24 per day. The typical ganja cigarette or cigar, termed a spliff is roughly a four-inch-long paper cone and contains about two to three grams of ganja with a delta 9 THC content of about 2.9% on the average (range of 0.7-10.3%) mixed with about half of a Tobacco cigarette. Also many smoke ganja in a Chillum pipe using very deep inhalation to fill their lungs with smoke. They consume 14 pipe fulls per week on the average, with a range of 1-25 per week.
No significant differences in neurological abnormalities, electroencephalographic abnormalities, hemochemical changes including liver function, urinalysis, chest X-ray abnormalities or chromosome damage in lymphocytes were found in the users or controls.
One user had a long history of bronchial asthma and another had a mild case of Jamaican neuropathy, but nothing suggests these disabilities were in any way related to ganja use. Minor electrocardiographic abnormalities were present in about one-third of both users and controls. This may be related to a syndrome of unknown etiology known as Jamaican cardiomiyopathy.
Thorough physical examination and hematological studies revealed only minimal significant differences between ganja smokers and non-ganja smoking controls. Comprehensive evaluation of red blood cell indices revealed that the ganja smokers had significantly higher hemoglobin levels and packed red cell volumes (hematocrit) than the non-ganja smokers.
These hematologic findings are compatible with those reported recently (Sangan and Balberzak, 1971) for heavy tobacco cigarette smokers. The authors noted that cigarette smoking causes a functional tissue hypoxia due to deficits in lung func tionwith resultant arterial oxygen unsaturation. Thus, an increased demand is placed on the bone marrow to provide more red blood cells to increase the oxygen carrying capacity of the blood.
In addition to the heavy smoking of ganja in spliffs and pipes, 27 of the 30 ganja smokers were tobacco smokers, and several have smoked tobacco cigarettes heavily. 19 of the 30 non-ganja smokers were tobacco cigarette smokers and tended to be light tobacco cigarette smokers.
Thus, the data appears to suggest that a combination of factors including number of years and quantity of cigarette smoking, ganja spliff smoking and ganja chilum pipe smoking is significantly correlated with the hematological changes indicative of functional hypoxia. However, pulmonary function studies did not demonstrate significant decrements correlated with ganja or tobacco smoking.
No significant differences were found between groups by a thorough psychiatric and psychological examination. All subjects were judged to be in normal mental health. Subjects were administered a battery of standardized reliable American psychological tests known to be sensitive to impairment in brain function. These tests were not culture free so that comparison of performance, between Jamaicans and Americans is meaningless Nineteen tests evaluating 47 variables were performed including one personality test, three tests of intelligence and verbal abilities, and 15 neuropsychological tests.
Two of 47 variables had statistically significant differences between ganja smokers and non-smokers. The smokers scored higher on the digit span subtest of the Wechsler Adult Intelligence Scale and bad a more centralized personality organization on the Lowenfeld Mosaic Test.
Non-smokers had the best performance on the number of edge contacts with the non-dominant hand on the Holes Test. These few significant differences were considered chance findings by the investigators.
In general no consistent differences were found on these psychological tests between ganja smokers and non-smokers. The data clearly indicate that the long-term ganja use by these men did not produce demonstrable intellectual or ability deficits when they were without the drug for three days. No evidence in these results suggest permanent brain damage.
The alleged role of ganja in producing personality change in the direction of a loss of competitive striving and an unwillingness to work, termed the amotivational syndrome was also investigated.
Based on clinical impressions gained from careful sociological and psychological techniques, the investigators noted that the chronic ganja smoker differed little in work habits or record from his matched control. No evidence of an amotivational syndrome was found. In fact, the subjects believe ganja has a functional value as a work adjunct. It provides energy for work and helps them do arduous boring jobs.
In the Jamaican culture, ganja may produce a "motivational syndrome". In an objective videotape evaluation of work energy output and ganja smoking, ganja use did not lower productivity on simple repetitive tasks, such as woodcutting which requires compulsive concentrated effort.
A study of cultivators points up the relationship of population, land, and economic pressures to ganja use. In the area studied land resources are scarce, farms small and cultivation difficult on the hilly slopes. Market conditions determine income from cash crops and restrictions on migration maintain population pressures on limited resources.
For these farmers, the researchers suggest that ganja use, decreases total cultivated acreage and consolidates production while disruption of competition and social cohesiveness among the farmers is avoided.
These data may indicate that heavy ganja use during cultivation in farming situations with limited alternatives may serve to maintain the status quo. However, it is possible that the compulsive concentrated effort experienced by the cultivators with heavy ganja use may be productive in areas with good soil and climatic conditions where systematic weeding can increase crop yields.
As a result of the extensive anthropological study, the investigators believe that ganja use in Jamaica is a culturally determined phenomenon. A "ganja complex" exists which consists of closely related, learned patterns of behavior manifested by the members of the society.
The ganja complex appears to be functional for the working-class Jamaican. Various
elements Of the complex including economic, social and personal are interrelated in ways
that contribute to operation of the whole culture.
Dr. Salamuddin Weiss (1971) studied 1011 chronic hashish users in Kabul in order to obtain a general picture of the charas habit in Afghanistan.
Cannabis is cultivated in this tropical country. A concentrated product, charas, the resin obtained from the flowering tops of the female plant, is the preparation generally used. The most common method of smoking charas is in a clay water pipe called a Chelum. Next most commonly used is a pipe or needle and straw. Infrequently, charas is smoked in tobacco cigars or cigarettes. Chewing the leaves or drinking a charas mixture as a confection is quite rare.
Although charas smokers are found throughout society, they are predominantly found in certain groups. The ages of the subjects studied ranged from 13 to 70 years old. More than 75% were, married. Almost all were males.
Socioeconomic status was as follows: 70%, lower, 28% middle and 2% upper. 82% are illiterate, 27% had a primary school education and less than 1% had any higher education.
Most smoking occurs in groups of two to 20 friends in quiet out of the way places. Most users smoke several times a day. The longer one has smoked charas, the shorter the duration of the high and the more often the individual can smoke each day.
Weakness, sexual difficulties and physical impotence are commonly reported by smokers. Most report they have a good appetite and eat more than normal, but malnutrition is common.
One hundred chronic smokers were selected at random and examined medically: 93 were malnourished; no evidence of illness was found in 79 subjects; 13 showed signs of respiratory illness (bronchitis) ; 7 showed sleep disturbances and one had pulmonary tuberculosis. No deaths have been reported from charas overdose. One subject out of the 1,011 was known to be chronically psychotic.
A review of over 150,000 outpatient and inpatient psychiatric visits per year over the past 10 years revealed 20 short-term psychotic episodes yearly involving charas alone and 16, short-term psychotic episodes yearly involving both charas and other drugs. An absence of chronic mental illness related to charas use was noteworthy.
Most charas smokers commence use during their teens, gradually increasing their use about five or six times until they reach their highest dose between the ages of 20 to 40 years.
At the extreme, smokers have raised their daily dosage up to 10 times their starting dose within the first two years. They then gradually decrease their daily requirement by about 50% upon reaching their 60's. Generally, most smokers cease charas use after their 60's, but some. use extremely low doses for the rest of their lives.
I These patterns of use are consistent with the development of tolerance. Additionally, chronic smokers note they are able to use larger doses than they did when they began use without any significant signs of intoxication. Also after stopping charas use for a few days or months, the users report they restart use at smaller doses to achieve the desired effect.
No physical dependence was noted. Marked psychological dependence was present which makes it difficult to stop their habitual use. Discontinuation of charas use produced mild psychologic abstinence signs. These signs, generally include restlessness loss of appetite, sleeplessness, nervousness, headache, and gastrointestinal upset.
Most smokers after discontinuation of use are quite able to live with their families and perform their jobs without discomfort. Most chronic smokers return to charas use within days or months. Out of a group of 100 randomly selected ex-smokers who had used for eight to 22 years, 42 have not returned to charas use, 16 use occasionally and 42 have returned to daily use within one to 13 months.
Most common explanation given by the subjects for restarting use were to continue close relationships with charas using friends and lack of a busy job.
A group of 100 opium addicts were selected at random from the community; 51 of these started their drug use with charas and later substituted opium for charas.
Generally, charas smokers report that they become faster in their daily jobs, but observation reveals a slowness in these activities. The ability to perform a non-complicated job is comparable to non-charas smokers. They tend to be cooperative but lazy persons. They tend to be more theoretical than practical and avoid making decisions. They do not demonstrate creativity or contribute significantly to the improvement of their community.
Marihuana has been used by man in countries around the world for many centuries. Scientifically, more is known about marihuana's effects than many other botanical substances consumed by man.
Marihuana is one of several preparations from the plant, cannabis sativa. The plant contains many different chemicals, but tetrahydrocannabinol appears to be the major active psychopharmacologic ingredient. The potency of the preparation is determined by the THC content, which varies according to the origin of the seed, the conditions of cultivation, and the extent of manicuring.
Several important factors exert significant influences on the psychopharmacological effect. These include dose, method of use, set and setting, and pattern of use including frequency and duration of use.
The acute subjective experience is dose-dependent. At low doses commonly used in this country a mild intoxication occurs, but at higher doses psychotomimetic experiences can occur. Few consistent physiological effects are noted. No pathologic bodily changes have been conclusively demon, strafed from acute use. Subtle effects on recent memory, psychomotor function, and social behavior have been demonstrated.
The margins of safety between the effective dose and the toxic dose is quite large. No human fatalities have been noted in this country caused by marihuana. The most common adverse reactions are becoming too intoxicated, and the acute anxiety panic reaction. Both of these are transient and related to dose consumed as well as set and setting factors.
Acute psychotic, reactions are quite rare. They usually last a few days to weeks and occur in predisposed persons either with preexisting mental disorders or borderline personalities especially under stressful conditions. Transient acute brain syndrome or toxic psychosis is possible at extremely large doses.
Evidence has accumulated which indicates that differential tolerance does develop at least, in persons who smoke large amounts of marihuana several times a day. Development of tolerance to the depressant effects on behavior appears to precede development of tolerance to the intoxicant effect.
Physical dependence has not been demonstrated. Little, if any, psychological dependence is present in most intermittent marihuana users. Moderate psychological dependence occurs in moderate to heavy users and marked psychological dependence has been described in very heavy chronic users.
Some detrimental effects have been conclusively linked to short- and long-term marihuana use for very heavy users. The most frequently reported change in the heavy, long-term smokers of large quantities of potent preparations is chronic bronchitis comparable to that developed by a heavy, long-term tobacco cigarette smoker. A chronic cannabis psychosis probably occurs rarely in heavy chronic, hashish smokers in Eastern countries. Most psychotic episodes are the acute variety and clear in a few days to weeks. No objective evidence has been demonstrated that even very heavy, long-term hashish use causes organic brain damage.
Objective studies of chronic, heavy smokers of potent preparations have not causally
linked this drug with the amotivational syndrome which has been described by many
clinicians. Almost all chronic, heavy hashish smokers are indistinguishable from their
peers in the lower socioeconomic strata of their respective societies in social behavior,
work performance, mental status and overall life style.
,Abel, E: "Marihuana and Memory," Nature, 227 (5263) 1151-1152 (1970).
Abel, E. L.: "Effects of Marihuana on the Solution of Anagrams, Memory and Appetite," Nature, 231: 260-261 (1971).
Abel, E. L. "Marihuana and Memory: Acquisition or Retrieval," Science, 173: 1038-1040 (1971).
Abel, E. L.: "Retrieval of Information After Use of Marihuana, " Nature, 231 (5297) : 58 (1971).
Abelson, H. Cohen, R. and Sehrayer. D.: Public Attitudes Toward Marihuana, Princeton: Response Analysis (1972).
Adams R.: "Marihuana," Bulletin of the New York Academy of Medicine, 18: 705-730 (1942).
Adams, R.: "Marihuana," Harvey Lectures, Series 37: 16,8-197 (1941-1942).
Advisory Committee on Drug Dependence, Cannabis (Wootton Report), London: Her Majesty's Stationery Office (1968).
Agurell, S. and Leander, K.: "Stability, Transfer and Absorption of Cannobinoid Constituents of Cannabis (Hashish) During Smoking," Acta Pharmaceutica, Succica, 8: 685 (1971).
Aldrich, C. K.: "The Effect of a Synthetic Marihuana-Like Compound on Musical Talent as Measured by the Seashore Test," Public Health Reports, 59 (13) : 431-433 (1944).
Allentuck, S. and Bowman, K. M.: "The Psychiatric Aspects of Marihuana Intoxication," American Journal of Psychiatry, 99: 248-251 (l942).
Ames, F.: "A Clinical and Metabolic Study of Acute Intoxication With Cannabis Sativa and Its Role in the Model Psychoses," Journal of Mental Sciences, 104 (437): 972-999 (1958).
Asuni, T.: "Socio-Psychiatric Problems of Cannabis in Nigeria," United Nations Bulletin on Narcotics, 16 (2) 17-28 (1964).
Aubin, J.: "Le Test Evolutif dans l'Intoxication Chronique per le Kif," Algerie Med (1944).
Baker, A. A. and Lucas, E. G.: "Some Hospital Admissions Associated With Cannabis," Lancet, 1 (7580) : 148 (1969).
Baker-Bates, E. T.: "A Case of Cannabis Indica Intoxication," Lancet, I: 811 (1935).
Barry, H. and Kubena, R. K.: "Repeated High Doses of Delta-l-Tetrahydrocannabinol Enhance Acquisition of Shock Avoidance in Rats," Proceedings 79th Annual Convention of the American Psychological Association, 749-750 (1971)
Bartolucci, G. Fryer, L., Perris, C. and Shagass, C.: "Marihuana Psychosis: A Case Report," Canadian Psychiatric Association Journal, 14 (1) 77-79 (1969).
Baudelaire, C.:In: Ebin, D. (Ed.) The Drug Experience. First Person Accounts of Addicts, Writers, Scientists and Others, New York: The Allon Press (1961), pp. 1640.
Beaubrun, M. H.: "The Pros and Cons of Cannabis Use in Jamaica," Prepared by the Department of Psychiatry, University of the West Indies as a Working Paper for Panel on Youth and Drugs, Costa Rica (January 8, 1971).
Benabud A.: "Psychopathological Aspects of the Cannabis Situation in Morroco: Statistical Data for 1956," United Nations Bulletin on Narcotics, 9(4) : 1-16 (1957).
Ben-Zui, Z., Mechoulam, R. and Burstein, S.: "Identification Through Synthesis of an Active A' (6) Tetrahydrocannabinol Metabolite,," Journal of American, Chemical Society, 92 (11) : 3468-3469 (1970).
Bercht, C. A. L., Kuppers, F. J. E. M., Lousberg, R. J. J. Ch. and Kalemink, C. A.: "Constituents Volatiles du Cannabis Sativa L.," United Nations ST/SOA/SER .5/29: 1-11 (July 22,1971).
Beringer, K., et al.: "Zur Klinik des Hashisclirausches," Der Nervenarzt, 5 (7) : 337-350 (1932).
Bernhardson, G.: "Cannabis Psychosis," Svenska Lakartidn, 66: 1230-1234 (1969).
Bey, D. R., and Zecchinelli, V. A.: "Marihuana as a Coping Device in Vietnam," Military Medicine, 136 (5) : 448-450 (1971).
Bialos, D.: "Adverse Marihuana Reactions: A Critical Examination of the Literature with Selected Case Material," American Journal of Psychiatry, 127 (6) : 119-123 (1970).
Bloomquist, E. R.: "Marihuana: Social Benefit or Social Detriment?" California Medicine, 106: 346-353 (1967). Blumenfield, M.: "Flash-back Phenomena in Basic Trainees who Enter the U.S. Air Force," Presented 17th Annual Conference of Air Force Behavioral Scientists, School of Aerospace Medicine, San Antonio (January 1970).
Roroffka, A.: "Mental Illness and Indian Hemp in Lagos," East African Medical Journal, 43 (9) : 377-384 (1966). Bouquet, J.: "Cannabis," United Nations Bulletin on Narcotics, 2 (4) : 14-30 (1950) ; 3 (1) : 22-45 (1951). Bouquet, J.: "Marihuana Intoxication (letter)," Journal of the American Medical Association, 124: 1010-1011 (1944).
Bright, T. D., Kiplinger, G. F., Brown, D. Phillips, J. and Forney, R. B.: "Effects of Beta Adrenergic Blockade on Induced Tachycardia," Committee on the Problem of Drug Dependence, II: 1737-1744 (1971).
Brill, N. 0. Crumpton, E., Frank, 1. M., Hochman, J. S., Lomax, P., McGlothlin, W. H. and West, L. J.: "The Marihuana Problem," Annals of Internal Medicine, 73 (3) : 449-465 (1970).
Bromberg, W.: "Marihuana, A Psychiatric Study," Journal of the American Medical Association, 113: 4-12 (1939).
Bromberg, W.: "Marihuana Intoxication, A Clinical Study of Cannabis Sativa Intoxication," American Journal of Psychiatry, XCI (2) : 303-330 (1934).
Burstein S. and Rosenfeld, J.: "The Isolation and Characterization of a Major Metabolite of Delta 9-THC," Acta Pharmaceutica, Suecica, 8: 699-700 (1971).
Burstein, S. H., Alenezes, F., Williamson, E. and Mechoulam, R.: "Metabolism of Delta 9-Tetrahydrocannabinol. An Active Marihuana Constituent," Nature, 225: 87-88 (1970).
Caldwell, D. F., Myers, S. A., Domino, E. P. and Merriam, P. E.: "Auditory and Visual Threshold Effects of Marihuana in Man," Perceptual and Motor Skills, 29: 755759 (1969).
Caldwell, D. F., Myers, S. A., Domino, E. F. and Merriam, P. E.: "Auditory and Visual Threshold Effects of Marihuana in Man," Addendum, Perceptual and Motor Skills, 29: 922 (1969).
Caldwell, D. F., Myers, S. A., Domino, E. F. and Merriam, P. E.: Psychotomimetic Drugs, New York: Raven Press (1970),pp.299-321.
Campbell, A. M. G., Evans, Al., Thomson, J. L. G. and Williams, M. J.: "Cerebral Atrophy in Young Cannabis Smokers," Lancet, II: 1219-1226 (1971).
Carakushansky, G., Neu, R. F. and Gardner, L. I.: "Lysergide and Cannabis As Possible Teratogens in Man," Lancet, 11: 150-151 (1969).
Carlini, E., Hanaoni, A., Bieniek, D. and Korte, F.: "Effects of (-)Delta 9-Trans-Tetrahydrocannabinol and a Synthetic Derivative on Image Performance of Rats," Pharmacology, 4 (6) : 359-368 (1970).
Carlini, E. A.: "Tolerance to Chronic Administration of Cannabis Sativa (Marihuana) in Rats," Pharmacology 1: 135-142 (1968).
Charen, S. and Perelman, L.: "Personality Studies of Marihuana Addicts," American Journal of Psychiatry, 102: 674-682 (1946).
Chopra, G. S.: "Alan and Marihuana." International Journal of the Addictions, 4 (2) : 215-247 (1969).
Chopra, G. S.: "Marihuana and Adverse Psychotic Reactions," U.N. Bulletin on Narcotics, 23 (3) :15-21 (1971). Chopra, 1. C. and Chopra, R. N.: "The Use of the Cannabis Drugs in India," United Nations Bulletin on Narcotics, 9 (1) : 4-29 (1957).
Chopra, R. N.: "Drug Addiction in India and Its Treatment," Indian Medical Gazette, 70 (3) : 121 (1935). Chopra, R. N.: "Use of Hemp Drugs in India," Indian Medical Gazette, 75 (6) : 356-367 (1940). Chopra, R. N. and Chopra, G. S.: "The Present Position of Hemp-Drug Addiction in India," Indian Medical Besearch Memoirs, (31) : 1-119 (1939).
Chopra, R. N., Chopra, G. S. and Chopra, 1. C.: "Cannabis Sativa. in Relation to Mental Diseases and Crime in India," Indian Journal of Medical Research, 30 (1) 155-171 (1942).
Christensen, H. D., Freudenthal, R. I., Gidley, J. T., Rosenfeld, R., Boegli, G., Testino, L., Brine, D. R., Pitt, C. G. and Wall, .M. E.: "Activity of A' and Delta 9-Tetrahydrocannabinol and Related Compounds in the Mouse," Science, 172 (3979) : 165-l67 (1971.).
Christozov, C. : "Morrocan Aspects of Cannabis Intoxication in the Light of Studies on Chronic Mental Patients," Maroc Medical, 44: 630-642, 866-889 (1965). Clark, L. D., Hughes, R. and Nakashima, E. N.: "Behavioral Effects of Marihuana: Experimental Studies," Archives of General Psychiatry, 23 (3) : 193-198 (1970). Clark, L. D. and Nakashima, E. N.: "Experimental Studies of Marihuana," American Journal of Psychiatry, 125: 379-384 (1968).
Claussen, U. and Korte, P.: "Haschisch XV," Liebigs Annals of Chemistry, 713: 162-165 (1968).
Colbach, E. Al. and Crowe, R. R.: "Marihuana Associated Psychosis in Vietnam," Military Medicine, 135 (7) : 571573 (1970).
Cole, J. Al., Pieper, W. A. and Rumbaugh, D. M.: "Effects of Delta-9-Tetrahydrocannabinol on Spaced Responding in Great Apes," Communications in Behavioral Biology, 6: 1-9 (1971).
Curtis, H. C. and Wolfe, J. R.: "Psychosis Following the Use of Marihuana with Report of Cases," Journal of the Kansas Medical Society, 40: 515-517, 526-528 (1939).
Dally, P.: "Undesirable Effects of Marijuana," British Medical Journal, 367 (1967).
Deakin, S.: "Death from Taking Indian Hemp," Indian Medical Gazette, 71 (1880).
Defer, B. and Diehl, M. L.: "Les Psychoses Cannabiques Aigues: A Propose de 560 Observations," Annales Medico Psychologiques, 126 (2) : 260-266 (1968).
Deliyannakis, E. C., Paragopoulos, C. and Huott, A. D.:
"The Influence of Hashish on the Human EEG," Clinical EEG, 1: 108-117 (1970).
Deneau, G. A. and Kaymakcalan, S.: "Physiological and Psychological Dependence to Synthetic Delta 9-Tetrahydroeannabinol (THC) in Rhesus Monkeys," The Pharmacologist, 13 (2) :246 (1971).
Dhunjibhoy, J. E.: "A Brief Resume of the Types of Insanity Commonly Met With in India With a Full Description of 'Indian Hemp Insanity' Peculiar to the Country," Journal of Mental Science, 76: 254-264 (1930).
Dhunjibhoy, J. E.: "The Role of 'Indian Hemp' In Causation of Insanity in India," Far Eastern Association of Tropical Medicine, Transactions of 7th Session, I : 400407 (1928).
Dingell, J. W., Wilcox, H. G. and Klausner, H. A.: "Biochemical Interactions of Delta 9-Tetrahydrocannabiol," The Pharmacologist, 13: 296 (1971).
Domino, E. F.: "Human Pharmacology of Marijuana Smoking," Presented 71st Annual Meeting of American Society for Clinical Pharmacology and Therapeutics (1970).
Domino, E. F.: "Neuropsychopharmacologic Studies of marihuana : Some Synthetic and Natural THC Derivatives in Animals in Man," Annals of the New York Academy of Science, 191: 166-191 (1971).
Domino, E. F., Hardman, H. F. and Seevers, Al. H.: "Central Nervous Systems Actions of Some Synthetic Tetrahydrocannabinol Derivatives," Pharmacological Review (in press 1972).
Doorenbos, N. J., Fetterman, 11. S., Quinby, M. W. and Turner, C. E.: "Cultivation, Extraction and Analysis of Cannabis sativa L.," Annals of the New York Academy of Science, 191: 3-14 (1971).
Dornbush, R. L., Fink, M. and Freedman, A. M.: "Marijuana, Memory and Perception," American Journal of Psychiatry, 128 (3) : 194-197 (1971).
Dorrance, J., Janiger, 0. and Teplitz, L.: ".In Vivo Effects of Illicit Hallucinogens on Human Lymphocyte Chromosomes," Journal of the American Medical Association, 212 (9) : 1488-1491 (1970).
Dott, A. B.: "Effect of Marihuana on Risk Acceptance in an Automotive Simulator," Prepared by the U.S. Public Health Service, Injury Control Research Laboratory, Providence, Rhode Island: Contract No. ICRL-RR-71-3 (June 1971).
Elsmore, T. P.: "Some Behavioral Effects of Delta-9Tetrahydrocannabinol," Current Trends in Army Medical Sciences Psychology, 12-19 (1970).
Ewens, G. P. W.: "Insanity Following the Use of Indian Hemp," Indian Medical Gazette, 39: 401-413 (1904).
Fahrenholtz, K. E., Lurie, M. and Kierstead, R. W.: "The Total Synthesis of Delta 9-Tetrahydrocannabinol and Four of Its Isomers," Journal of the American Chemical Society, 89: 5934-5941 (1967).
Fahrenholtz, K. E., Lurie, M. and Kierstead, R. W.: "Total Synthesis of Delta 9-Tetrahydrocannabinol and of dl-Y.Tetrahydrocannabinol, Racemates of Active Constituents of Marihuana," Journal of the American Chemical Society, 88: 2079-2080 (1966).
Favazza, A. and Domino, E. F.: "Recurrent LSD Experience (Flashbacks) Triggered by Marihuana," University of Michigan Medical Center Journal, 35: 214-216 (1969).
Fere, C.: "Note sur l'Influence du Haschisch sur le Travail," Comptes Rendus Hebdomadaires des Seances de la Societe de Biologic, (Ileme serie), 3: 696-700 (1901).
Ferraro, D. P., Grilly, 1). AL and Lynch, W. C.: "Behavioral Effects of Small Doses of Marihuana Extract in Chimpanzees," Prepared for the National Institute of Mental Health, Contract No. HSM 42-21-75, Department of Psychology, University of New Mexico, Albuquerque (November 1971).
Ferraro, D. P., Grilly, D. M. and Lynch, W. C.: "Comparison of Behavioral Effects of Synthetic Delta 9-Tetrahydrocannabinol and Marihuana Extract in Chimpanzees," Prepared for the National Institute of Mental Health, Contract No. HSM 42-21-75, Department of Psychology, University of New Mexico, Albuquerque (November 1971).
Ferraro, D. P., Grilly, D. M. and Lynch, W. C.: "Study of Long-Term Effects of Marihuana in Chimpanzees," Prepared for the National Institute of Mental Health, Contract No. HSM 42-21-75, Department of Psychology, University of New Mexico, Albuquerque (November 1971).
Fetterman, P. S., Keith, E. S., Waller, C. W., Guerrero, O., Doorenhos, N. J. and Quimby, M. W.: "MississippiGrown Cannabis Sativa 1: Preliminary Observation on Chemical Definition 'of Phenotype and Variation in Tetrahydrocannabinol Content Versus Age, Sex, and Plant Part," Journal of Pharmaceutical Sciences, 60 (8) :1240-1249 (1971).
Fink, M.: "The Biology of Cannabis; The State of Our Knowledge, 1970," Presented at American Public Health Symposium on Cannabis, San Francisco (May 1970).
Fink, M.: "Summary Report: Marihuana Study Program 278M7C," Prepared for the National Institute of Mental Health, (November 1971).
Fink, M., Professor of Psychiatry and Dornbush, R. L., Assistant Professor of Psychiatry, Personal Communication, New York Medical College, December 30, 1971.
Fink, M., Stefanis, C. and Staffs: "Interim Report: Study of Marihuana Users in Greece," Prepared for the National Institute of Mental Health, Contract No. HSM 42-70-98, Department of Psychiatry, New York Medical College (October 1971).
Finley, T. N., Personal Communication, Director, Pulmonary Laboratory, 'Mount Zion Hospital and Medical Center, San Francisco, California, December 13, 1971.
Foltz, R. L., Fentinan, A. F., Leighty, E. G., Walter, J. L., Drewes, 11. R., Schwartz, W. E.. Page, T. P. and Truitt, E. B.: "Metabolite of Trans-Delta 8-Tetrahydrocannabinol: Identification and Synthesis," Science, 168: 844-845 (1970).
Foltz, R. L., Kinzer, G. W., Mitchell, R. I., and Truitt, E. B.: "The Fate of Cannabinoid Components of Marihuana During Smoking," to be published (1972).
Forney, It. B.: "Toxicology and Pharmacology of Marihuana," Presented at New York Academy of Science, (May 1971).
Forrest, D. V.: "Marihuana to Heroin . . . A Missing Link?" American Journal of Psychiatry, 127 (5) : 164165 (1970).
Francois, G. R., Barrat E., Russel, G.. Barker, T. and White, R. B.: "The Marihuana Dilemma-A Clinical and Experimental Approach," Presented at Annual Meeting of the American Psychiatric Association, (May 1970).
Frank, 1. M., Hopler, R. S., Stier, S. and Rickles, W. H.: "Marihuana, Tobacco and Functions Affecting Driving," Presented at Annual Meeting of the American Psychiatric Association, (May 1971).
Frank, 1. R., Assistant Professor of Psychiatry and Hepler, R. S., Assistant, Professor of Opthmalogy, Personal Communication of Preliminary Data, University of California, School of Medicine, Los Angeles, California, September 1971.
Frankenhein, J. M., McMillan, D. E. and Harris, L. S.: "Effects of I-Delta 9 and I-Delta 8 Trans-Tetrahydrocannabinol on Scheduled Controlled Behavior of Pigeon," Journal of Pharmacology Experimental Therapeutics, 178: 241-252 (1971).
Fraser, J. D.: "Withdrawal Symptoms in Cannabis Indica Addicts," Lancet, II: 747-748 (1949).
Freedman, A. M. and Fink, M.: "Cannabis Psychosis," Presented at Symposium on Biochemical and Pharmacological Aspects of Dependence and Reports on Marihuana Research, Amsterdam (October 1971).
Freedman, H. L. and Rockmore, M. J.: "Marihuana, a Factor in Personality Evaluation and Army Maladjustment," Journal of Clinical Psychopathology, 7: 765-782 (Part 1) ; 8: 221-236 (Part H) (1946).
Galanter, M., Wyatt, It. J., Weinberger, L., Weingartner, H., Vaughan, T. B. and Roth, W. T.: "Delta-9-Trans-Tetrahydrocannabinol Administered by Smoking: Studies of Blood Levels, Pulse and Subjective Effects," Science, (in press 1972).
Gaoni, Y. and Mechoulani, R.: "Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish," Journal of the American Chemical Society, 86: 16461647 (1964).
Gary, N. E. and Keylon, V.: "Intravenous Administration -of Marihuana," Journal of the American Medical Association, 211 (3) : 501 (1970).
Gaskill, 11. S.: "Marihuana, An Intoxicant," American Journal of Psychiatry, 102: 202-204 (1945).
Geher, W. F.: "Effects of Marihuana Extract on Petal Hamsters and Rabbits," Toxicology and Applied Pharmacology, 14: 276-282 (1969).
Geber, W. F. and Schramm, L.: "Teratogenicity of Marihuana Extract as Influenced by Plant Origin and Seasonal Variation," Archives Internationales de Pharmacodynamie et de Therapie, 177 (1) : 224-239 (1969).
Gelehrter, 1. D.: "Lysergic Acid Diethylamide (LSD) and Estrophy of the Bladder," Journal of Pediatrics, 77: 1065-1066 (1970).
George, H. R.: "Two Psychotic Episodes Associated With Cannabis," British Journal of Addiction, 65: 119-121 (1970).
Gill, E. IV.: "Propyl Homologue of Tetrahydrocannabinol:
Its Isolation from Cannabis, Properties and Synthesis," Journal of the Chemical Society Organic, (3) : 579-582 (1971).
Gill, E. W., Paton, W. D. M. and Pertwee, R. G.: "Preliminary Experiments on the Chemistry and Pharmacology of Cannabis," Nature, 228: 134-136 (1970).
Gilmour, D. G., Bloom, A. D., Leli, K. P., Robbins, E. S. and Maximilian, C.: "Chromosomal Aberrations in Users of Psychoactive Drugs," Archives of General Psychiatry, 24: 268-272 (1971).
Goode, E.: "Drug Escalation: Marihuana Use as Related to the Use of Dangerous Drugs," (October 1971).
Goode, E.: The Marihuana Smokers, New York: Basics Book, Inc. (1970).
Grinspoon, L.: "Marihuana," Scientific American, 221: 1725 (1969).
Grossman, W.: "Adverse Reactions Associated With Cannabis Products in India," Annals of Internal Medicine, 70 (3) : 529-533 (1969).
Haines, L. and Green, W.: "Marihuana Use Patterns," British Journal of Addiction 65 (4) : 347-362 (1970). Halikas, J. A., Goodman, D. W. and Guze, S. B.: "Marihuana Effects: A Survey of Regular Users," Journal of the American Medical Association, 217: 692-694 (1971).
Halikas, J. A., Goodman, D. W. and Guze, S. B.: "Marihuana Use and Psychiatric Illness," Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, (submitted for publication 1972).
Hamaker, S. T. A.: "Case of Overdose of Cannabis Indica," Therapeutic Gazette, 7: 808 (1891).
Harris, R. T., Personal Communication, Psychological Research, Texas Research Institute of Mental Sciences, Houston, August, 1971.
Harris, R. T., Watters, W. H. and Henderson, G.: "Evaluation of Abuse Potential A' THC in Rhesus Monkeys," (unpublished) 1972).
Harris, R. T., Watters, W. H. and McLendon, D.: "Behavioral Effects in Rhesus Monkeys of Repeated Intravenous Doses of Marihuana Extract Distillate," (unpublished 1972).
Hecht, F., Beals, R. K., Lees, M. H., Jolly, H. and Roberts, P.: "Lysergic-Acid-Diethylamide and Cannabis as Possible Teratogens in Man," Lancet, II: 1087 (1968)
Heiman, E. M.: "Marihuana Precipitated Psychosis in Patient Evacuated to CONUS," USARU Medical Bulletin, 40 (9) :75-77 (1968).
Henderson, A. H. and Pugsley, D. J.: "Collapse After Intravenous Injection of Hashish," British Medical Journal, 3: 229-230 (1968).
Hepler, R. S., Frank, I. A. and Ungerleider, J. T.: "The Effects of Marijuana Smoking on Pupillary Size," (unpublished 1971).
Heyndrickx, A., Scheiris, C. and Schepens, P.: "Toxicological Study of a Fatal Intoxication in Man Due to Cannabis Smoking," Journal de Pharmacie de Belgigue, 24: 371-376 (1969).
Hively, R. L., Mosher, W. A. and Hoffmann, F. W.: "Isolation of Trans-Delta 9-Tetrahydrocannabinol From Marijuana," Journal of the American Chemical Society, 88: 1832-1833 (1966).
Ho, B. T., Fritellie, G. E., Englert, L. F., McIsaac, W. M. and Idanpaan-Heikkila, J. E.: "Marihuana: Importance of the Route of Administration," Journal of Pharmacy and Pharmacology, 23: 309--310 (1971).
Hochman, J. S. and Brill, N.: "Chronic Marihuana Usage and Liver Function," Lancet, 11 (7728) : 818 (1971).
Hollister, L. E.: "Human Pharmacological Studies on Cannabis," Acta Pharmaceutica Suecica, 8: 673 (1971).
Hollister, L. E.: "Hunger and Appetite After Single Doses of Marihuana, Ethanol and Dextroamphetainine," Clinical Pharmacology and Therapeutics, 12 (1) : 44-49 (1971).
Hollister, L. E.: "Marilhuana in Man: Three Years Later," Science, 172: 21-29 (1971).
Hollister, L. E.: "Status Report on Clinical Pharmacology of Marihuana," Annals of the New York Academy of Science, 191: 132-141 (1971).
Hollister, L. E.: "Steroids and Moods: Correlations in Schizophrenics and Subjects Treated with Lysergic Acid Diethylamide (LSD), Mescaline, Tetrahydrocannabinol, and Synhexyl," Journal of Clinical Pharmacology, 9: 24-29 (1969).
Hollister, L. E. and Gillespie, H. K.: "Marihuana, Ethanol and Dextroamphetamine: Mood and Mental Function Alterations," Archives of General Psychiatry, 23 (3) 199-203 (1970).
Hollister, L. E.. Moore, F., Kanter, S. and Noble E.:
"Delta-l-Tetrahydrocannabinol, Synhexyl and Marihuana Extract Administered Orally in Man: Catecholamine Excretion, Plasma Cortisone Levels and Platelet Serotonin Content," Psychopharmacologia (Berlin), 17 (4): 354-360 (1970).
Hollister, L. E., Richards, R. K. and Gillespie, H. K.: "Comparison of Tetrahydrocannabinol and Synhexyl in Man," Clinical Pharmacology and Therapeutics, 9 (6) 783-791 (1968).
Hollister, L. E., Sherwood, S. L. and Cavasino, A.: "Marihuana and the Human Electroencephalogram," Pharmacological Research Communications, (in press 1971).
Hughes, J. E., Steahly, L. 11. and Bier, M. M.: "Marihuana and tile Diabetic Coma,"Journal of the American Medical Association, 214 (6) : 1113-1114 (1970).
IdinpiRin-Heikkila, J., Fritchie, G. E., Englert, L. F., Ho, B. T., and McIsaac, IV. 'M.: "Placental Transfer of Tritiated (l)-NO-Tetrahydrocannabinol," New England Journal of Medicine, 281: 330 (lW9).
Iddanpaan-Heikkila, J. E., McIsaac, W. M. and Ho, B. T.:
",A' THC Distribution in Monkeys, Mice and Hamsters," Presented at the International Symposium on the Chemistry and Biological Activity of Cannabis, Stockholm (October 1971).
Indian Hemp Drug Commission Report 1893-1894, Silver Spring: Thomas Jefferson Publishing Company (RAprinted 1969), 1). 3281.
Isbell, H., Gorodetzsky, C. W., Jasinski, D. R., Claussen, U., Von Spulek, F. and Korte, F.: "Effects of (-) -Delta9-Trans-Tetrahydrocannabinol in Man," Psychopharmacologia (Berlin), 11 184-188 (1967).
Isbell, H. and Jasinski, D. R.: "A Comparison of LSD-25 With (-)-Delta-9-Trans-Tetrahydrocannabinol (THC) and Attempted Cross Tolerance Between LSD and THC," Psychopharmacologia, 14: 115-123 (1969).
Isbell, H., Jasiuski, D. R., Gorodetsky, C. W., Korte, P., Claussen, U., Haage, M., Sieper, H. and Von Spulak, F.: "Studies on Tetrahydrocannabinol," Bulletin, Problems of Drug Dependence, National Academy of Science, Division of Medical Science, 4832-4846 (1967).
Joachlinoglu, G.: Ciba. Foundation Study Group 21, 10, (1965).
Johnson, B. D.: "',social Determinants of the Use of 'Dangerous Drugs' by College Students," Columbia University, Doctorial Thesis (.June, 1971).
Johnson, S. and Domino, E. F.: "Some Cardiovascular Effects of Marihuana Smoking oil Normal Volunteers," Clinical Pharmacology and Therapeutics, 12 (5) : 762768 (1971).
Jones, R. and Stone, G.: "Psychological Studies of Marihuana and Alcohol in Man," Psychopharmacologia (Berlin), 18 (1) : 108-117 (1970).
Jones, R. T.: "The Marihuana Induced 'High': Influence of Expectation, Setting and Previous Drug Experience," Presented at Annual Meeting of the Federations of American Societies for Experimental Biology, Chicago (April 1971).
Jones, R. T.: "Tetraliydrocannabinol and the Marihuana Induced Social 'High' or The Effects of the Mind on Marihuana," Annals of the New York Academy of Scienee, 191: 155-165 (1971).
Kalant, N., LeBlanc, A. E. and Gibbins, R. J.: "Tolerance To, and Dependence On Some Non-Opiate Psychoactive Drugs, Pharmacological Reviews, 23 (3): 135-491 (1971).
Kaplan, H. S.: "Psychosis Associated with Marihuana,"
New York State Journal of Medicine, 71 (4) : 433-435 (1971).
Katz, M. Al., Waskow, 1. E., Almon, J.: "Characterizing the Psyehological State Produced by LSD," Journal of Abnormal Psychology, 73: 1-14 (1968).
Keeler, 11. H.: "Adverse Reaction to Marihuana," American Journal of Psychiatry, 124: 674-677 (1967).
Keeler, M. H.: "Alarihuana Induced Hallucinations,"
Diseases of the Nervous System, 29: 314-315 (1968). Keeler, M. H. and Reifler, C. B.: "Grand Alai Convulsions Subsequent to Marihuana Use: Case Report," Di8eam of the Nervous System, 28: 474-475 (1967).
Keeler, M. H., Reifler, C. B. and Liptzin, M. B.: "Spontaneous Recurrence of Marihuana Effect," American Journal of Psychiatry, 125: 384-386 (1968).
Kennedy, J. S. and Waddell, W. J.: "Whole Body Autoradiography of the Pregnant Mouse After Administration of C14-Delta 9-Tetrahydrocannabinol. (Delta 9-THC)," Federation Proceedings, 30: 279 (1971).
Keup, W.: "Psychotic Symptoms Due to Cannabis Abuse," Diseases of the Nervous System, 31 (2) : 119-126 (1970).
Kew, Al. C., Bersohn, L. and Siew, S.: "Possible Hepatotoxicity of Cannabis," Lancet, 1: 578-579 (1969).
King, A. B. and Cowen, D. L.: "Effect of Intravenous Injection of Marihuana," Journal of the American Medical Association, 210 (4) : 724-725 (1969).
King, A. B., Pechet, G. S. and Pechet, L.: "Intravenous Injection of Crude Marihuana," Journal of the American Medical Association, 214: 30 (1970).
Kiplinger, G. F., Manno, J. E., Rodda, B. E. and Forney, R. B.: "Dose-Response Analysis of the Effects of Tetrahydrocannabinol in Alan," Clinical Pharmacology and Therapeutics, 12 (4) : 650-657 (1971).
Klausner, H. A. and Dingell, J. V.: "The Metabolism and Excretion of Delta-9-Tetrahydrocannabinol in the Rat," Life Science, 10: 49-59 (1971).
Klein, F. K., Rapoport, H. and Elliott, H. W.: "Cannabis Alkaloids," Nature, 232: 258-259 (1971).
Kolansky, H. and Moore, W. T.: "Effects of Marihuana on Adolescents and Young Adults," Journal of the American Medical Association, 216 (3) : 486-492 (1971).
Kornhaber, A.: "Marihuana in an Adolescent Psychiatric Out Patient Population," Journal of the American Medical Association, 215 (12) : 1988 (1971).
Kubena, R. K., Perlach, J. L. and Barry, H.: "Corticosterone Elevation Mediated Centrally by Delta-1-Tetrahydrocannabinol in Rats," European Journal of Pharmacology, 14: 89-92 (1971).
Lambo. T. A.: "Medical and Social Problems of Drug Addiction in West Africa, With Special Emphasis on Psychiatric Aspects," United Nations Bulletin on Narcotics, 17 (1) : 3-13 (1965).
Lemberger, L.: "The Metabolism of the Tetrahydrocannabinols," Advances in Pharmacology and Chemotherapy, 10: (in press 1972).
Lemberger, L., Axelrod, J. and Kopin, I. J.: "Clinical Studies on the Disposition and Metabolism of A' THC and Their Correlation With Its Pharmacological Effects." Acta Pharmaceutical Suecica, 8: 692 (1971).
Lemberger, L., Axelrod, J. and Kopin, J.: "Metabolism and Disposition of A' Tetrahydrocannabinol in Man," Pharmacological Review, 23: 371-380 (1971).
Lemberger, L., Alexrod, J. and Kopin J.: "The Metabolism and Disposition of Delta-9-Tetrahydrocannabinol in Man," Federation Proceedings, 30: (1971).
Lemberger, L., Axelrod, J. and Kopin, J.: "Metabolism and Disposition of Delta-9-Tetrahydrocannabinol in Naive Subjects and Chronic Marihuana Users," Annals of New York Academy of Science, 191: 142-154 (1971).
Lemberger, L., Silberstein, S. D., Axelrod, J. and Kopin, 1. J.: "Marihuana studies on the Disposition and Metabolism of Delta-9-Tetrahydrocannabinol in Man," Science, 170 (3964) : 1320-1322 (1970).
Lemberger, L., Tamarkin, N. R., Axelrod, J. and Kopin, L: "Delta-9-Tetrahydrocannabinol: Metabolism and Disposition in Long Term Marihuana Smokers," Science, 173 (3991) : 72-74 (1971).
Lemberger, L., Weiss, J. L., Watanake, A. Al., Galanter, 1. M., Wyatt, R. J. and Cardon, P. V.: "Delta-9-Tetrahydrocannabinol's Temporal Correlation of the Psychological Effects and Blood Levels After Various Routes of Administration," New England Journal of Medicine (March 1972).
Lerner, P.: "The Precise Determinations of Tetrahydrocannabinol Isomers in Marihuana and Hashish," U.N. Bulletin on Narcotics, XXI(3) : 39-42 (1969).
Lewin, L.: Phantastica, Narcotic and Stimulating Drugs, New York: E. P. Dutton and Co., Inc. (1964), pp. 107122.
Lindemann, E.: "The Neurophysiological Effects of Intoxicating Drugs," American Journal of Psychiatry, 90: 1007-1037 (1933-1934).
Lipp, M. R.: "Marihuana Use By Medical Students," American Journal of Psychiatry, 128: 208-212 (1971). Lipparini, F., Decarolis, A. and Longo, U. A.: "Neuropharmacological Investigation of Some Tetrahyrocannabinol Derivatives," Physiology and Behavior, 4 (4) 527-532 (1969).
Liskow, B., Liss, J. L. and Parker, C. W.: "Allergy to Marihuana," Annals of Internal Medicine, 75: 571-573 (1971).
Loewe, S.: "Studies on the Pharmacology and Acute Toxicity of Compounds With Marihuana Activity," Journal of Pharmacology and Experimental Therapeutics, 88: 154-161 (1946).
Lomax, P.: "Acute Tolerance to the Hypothermic Effect of Marihuana in the Rat," Research Communications, Clinical Pathology and Pharmacology, 2: 159-167 (1971).
Ludlow, F.: The Hasheesh Eater: Being Passages from the Life of a Pythagorean, New York: Harper and Brothers (1857).
Lundberg, G. D., Adelson, J. and Prosnutz, E. H.: "Marihuana Induced Hospitalization," Journal of American Medical Association, 215 (1) : 121 (1971).
Magus, R. D. and Harris, L. S.: "Carcinogenic Potential of Marihuana Smoke Condensate," Federation Proceedings, 30 (2) : 277 (1971).
Mann, P. E. G., Cohen, A. B., Finley, T. N. and Ladman, A. J.: "Alveolar Macrophages. Structural and Functional Differences Between Non-Smokers and Smokers of Marihuana and Tobacco," Laboratory Investigation, 25 (2): 111-120 (1971).
Mann, P. E. G., Finley, T. N. and Ladman, A. J.: "Marihuana Smoking: A Study of Its Effects on Alveolar Lining Material and Pulmonary Macrophages Recovered by Bronchopulmonary Lavage," Journal of Clinical Investigations, 49 (6) : 60a-61a (1970).
Manno, B. R., Manno, J. E., Kilsheimer, G. S. and Forney, R. B.: "Response of the Isolated Perfused Rat Heart to Delta-9-Tetrahydrocannabinol (THC)," Toxicology and Applied Pharmacology, 10: 98 (1970).
Manno, J. E.: "Clinical Investigations With Marihuana and Alcohol," Department of Pharmacology and Toxicology, Indiana University, Doctoral Thesis (1970).
Manno, J. E., Kiplinger, G., Bennett, 1. F., Haine, S. E.
and Forney, It. B. : "Comparative Effects of Smoking Marihuana On Motor and Mental Performance lit Humans," Clinical Pharmacology and Therapeutics, 11 (6) : 808--815 (1970).
Manno, J. E., Kiplinger, G., Scholz, N. E., Forney, R. B., and Haine, S. E, : "The Influence of Alcohol and Marihuana on Motor and Mental Performance," Clinical Pharmacology and Therapeutics, 12: 202-211 (1970).
Marcovitz, E. and Myers, H. J.: "The Marihuana Addict in the Army," War Medicine, 6: 382-391 (1944).
Marten, G. W.: "Case Report: Adverse Reaction to the Use of Marihuana," Journal of the Tennessee Medical Association, 62 (7) : 627-630 (1969).
Martin, P. A.: "Cannabis and Chromosomes," Lancet, I: 370 (1969).
Masur, J. and Khazan, N.: "Induction by Cannabis Sativa (Marihuana) of Rhythmic Spike Discharges Overriding REM Sleep Cortigram in Rats," Life Sciences, 9 (1) 1275-1280 (1970).
Mayer-Gross, W., et al.: Clinical Psychiatry, London: Cassell (1960).
Mayor's Committee on -Marihuana: The Marihuana Problem in the City of New York: Sociological, Medical, Psychological and Pharmacological Studies, Lancaster: Cattell Press (1944).
McGlothlin, W. H.: "Marihuana: An Analysis of Use, Distribution and Control," Prepared for the Department of Justice, Washington, D.C. (June 1971).
McGlothlin, W. H.: "Use and Effects of Cannabis," Prepared for the National Commission on Marihuana and Drug Abuse, Washington, D.C. Department of Psychology, University of California, Los Angeles (January 1972).
McGlothlin, W. H., and Arnold, D. O.: "LSD Revisited: A Ten-Year Follow-Up of Medical LSD Use," Archives of General Psychiatry, 24: 35-49 (1971).
McGlothlin, W. H., Arnold, D. O., and Rowan, P. K.: "Marihuana Use Among Adults," Psychiatry, 33: 433443 (1970).
McGlothlin, W. H. and West, L. J.: "The Marihuana Problem: An Overview," American Journal of Psychiatry, 125: 126-134 (1968).
McIsaac, W., Personal Communication, Director, Texas Research Institute, Houston, Texas, October 28, 1971.
McIsaac, W., Harris, R. T. and Ho, B. T.: "Behavioral Correlates of Brain Distribution of Tetrahydrocannabinol," Acta Pharmaceutica Suecica, 8: 703 (1971).
McMillan, D. E., Dewey, W. L. and Harris, L. S.: "Characteristics of Tetrahydrocannabinol Tolerance," Annals of the New York Academy of Science, 191: 83-99 (1971).
McMillan, D. E., Harris, L. S., Frankenbeim, J. M., and Kennedy, J. S.: "(I)-Delta 9 Trans-TetrahydrocannabinoI in Pigeons: Tolerance to the Behavioral Effects," Science, 169: 501-503 (1970).
Mechoulam, R.: "Marihuana Chemistry," Science, 168 (3936): 1159-1166 (1970).
Mechoulam, R., Personal Communication, Professor, School of Pharmacy, Hebrew University, Jerusalem, October 28, 1971.
Mechoulam, R.: "Recent Advances in Cannabinoid Chemistry," Acta Pharmaceutica Suecica, 8: 675-676 (1971). Mechoulam, R. and Gaoni, Y.: "The Absolute Configuration of Delt 1-Tetrahydrocannabinol, The Major Active Constituent of Hashish," Tetrahedron Letters, 12: 1109-1111 (1967).
Mechoulam, R., Shani, A., Edery, H. and Grunfeld, Y.: "Chemical Basis of Hashish Activity," Science 169: 611-612 (1970).
Medical Staff, Pretoria Mental Hospital: "Mental Symptoms Associated With the Smoking of Dagga," South African Medical Journal, 12: 85 (1938).
Melges F. T., Tinklenberg, J. R., Hollister, L. E. and Gillespie, H. K.: "Marihuana and Temporal Disintegration," Science, 168 (3935) :1118-1120 (1970).
Melges, F. T., Tinklenberg, J. R., Hollister, L. E. and Gillespie, H. K.: "Marihuana and the Temporal Span of Awareness," Archives of General Psychiatry, 24: 464-567 (1971).
Melges, F. T., Tinklenberg, J. R., Hollister, L. E. and Gillespie, H. K.: "Temporal Disintegration and Depersonalization During Marihuana Intoxication," Archives of General Psychiatry, 23: 204--210 (1970).
Mendelson, J. H., Meyer, R. E., Rossi, A. M., Bernstein, J., Patch, V. D., Babor, T., O'Brien, J., Sagotsky, G., Reid, H., Salzman, C., Koehansky, G. E., Porrino, L., Becker, D., DeRubis, E., Cambria, T. J., Gallimore, P. B., Klinkert, C. E., Pope, S., Savitsky, J. B., Thompson, J.: "Behavioral and Biological Concomitants of Chronic Marihuana Smoking by Heavy and Casual Users," Prepared for the National Commission on Marihuana and Drug Abuse, Department of Psychiatry, Boston City Hospital (January 1972).
Merkus, F. W. H. M.: "Cannabivarin and Tetrahydrocannabivarin, Two New Constituents of Hashish," Nature, 232: 579 (1971).
Meyer, R. E., Pillard, R. C., Mirin, S. M., Shapiro, L.S.: "Administration of Marihuana to Heavy and Casual Users," American Journal of Psychiatry, 128 (3) : 198204 (1971).
Meyers, S. A. and Caldwell, D. F.: "Effects of Marihuana on Auditory and Visual Sensation," Research Bulletin, 20-22 (1969).
Meyers, S. A. and Caldwell, D. F.: "Effects of Marihuana on Auditory and Visual Sensation, A Preliminary Report," The New Physician, 18: 212-215 (1969).
Mikes, P. and Waser, P. G.: "Marihuana Components: Effects of Smoking of Delta 9-Tetrahydrocannabinol and Cannabinol," Science, 172: 1158-1159 (1971).
Milman, D. H.: "Adverse Effects of Cannabis," New York State Journal of Medicine, 71 (13) : 1675 (1971).
Miras, C. J.: "Some Aspects of Cannabis Action" In: Hashish: Its Chemistry and Pharmacology, Ciba Foundation Group No. 21, London: J. & A. Churchill (1965).
Miras, C. J.: Drugs and Youth, Springfield: C. C. Thomas (1969), pp. 191-198.
Miras, C. J.: Hashish, Its Chemistry and Pharmacology, Boston: Little, Brown & Co. (1965), pp. 37-52.
Miras, C. J.: "Marihuana and Hashish," UCLA lecture, (September 11, 1967).
Miras, C. J. and Coutselinis, A.: "The Distribution of Tetrahydrocannabinol in Humans," Report No. 24, United Nations Secretariat publication ST/SOA/SER. S/24 (November 1970).
Miras, C. J. and Coutselinis, A.: "The Presence of Cannabinoids in the Urine of Hashish Smokers," Report No. 25, United Nations Secretariat publication ST/SOA/ SER. S/25 (November 1970).
Mirin, S. M., Shapiro, L. M., Meyer, R. E., Pillar, R. C., Fisher, S.: "Casual Versus Heavy Use of Marihuana, A Redefinition of the Marihuana Problem," American Journal of Psychiatry, 127: 11.134-1140 (1971).
Moreau, J.: "Du Hachisch eit de I'Alientation, Mental," Etudes Psychologiques, 34: Libraire de Fortin, Masson, Paris (1845).
Nahas, G. C.: "Lethal Cannabis Intoxication," New England Journal of Medicine, 284: 792 (1971).
Nakazawa, K. and Costa, E: "Induction by Mothyloholan. threne of Delta 9 Tetrahydrocannabinol (A-THC) Metabolism in Rat Lung,11 Pharmacologist, 13: 297 (1971).
Neu, R. L., Powers, H. O., King, S. and Gardner, L. I.: "Cannabis and Chromosomes," Lancet, I-675 (1969).
New York Police Department, Annual Reports 1969 and 1970, City of New York (1969, 1970).
Nilsson, L. M., Agurell, S., Leander, K., Nilsson, J. L. G. and Widman, M.: "Cannabidiol: Structure of Three Metabolites Formed in Rat Liver," Acta Pharmaceutica Suecica, 8: 701 (1971).
Nisbet, C. T. and Vakil, F.: "Some Social and Economic Characteristics of UCLA Marihuana Users," Social Science Quarterly (in press 1971).
Ohlsson, A., Abou-Chaar, C. I., Agurell, S., Nilsson, 1. M., Olofsson, K. and Sandberg, F.: "Cannabinoid Constituents of Male and Female Cannabis Sativa," Bulletin on Narcotics, 23 (1) : 29-32 (1971).
Osinger, 0. and Fulginiti, S.: "Effects of Cannabis Sativa On Learning in Rats," Pharmacology, 3: 337-344 (1970). Pace, H. B., Davis, '.%I. W., Borgen, L. A.: "Teratogenesis and Mariliuana," Annals of the New York Academy of Science, 191: 123-131 (1971).
Paton, W. D. M. and Pertwee, R. G.: "The General Pharmacology of Cannabis," Acta Pharmaceutica Suecica, 8: 691 (1971).
Peebles, A. S. M. and Mann, H. W.: "Ganja as a Cause of Insanity and Crime in Bengal," Indian Medical Gazette, 49: 395-396 (1914).
Perez-Reyes, M. and Lipton, M. A.: "The Rate of Absorption and Excretion of Orally Administered Delta 9 Tetrahydrocannabinol to Man," Prepared for the National Institute of Mental Health, Contract #HSM 4269-62, Department of Psychiatry, University of North Carolina (July 1971).
Perez-Reyes, M., Lipton, M. A. and Wall, M. E.: "The Metabolism of Delta-9-Tetrahydroeannabinol in Human Subjects," Paper presented at the 5th World Congress of Psychiatry, Mexico City (December 1971).
Perna, D.: "Psychotogenic Effect of Marihuana," Journal of American Medical Association, 209: (7) 1085-1086 (1969).
Persaud, I. and Ellington, A.: "A Teratogenic Activity of Cannabis Resin," Lancet, 11 (7564) : 406-407 (1968). Persaud, 1. and Ellington, A.: "Cannabis in Early Pregnancy," Lancet, II: 1306 (1968).
Personal Communication To The Food and Drug Administration, Rockville, .Md., of Preliminary Experimental data-names withheld by request of the investigators, unpublished (1970).
Persyko, T.: "Marihuana Psychosis," Journal of the American Medical Assocation, 212 (9) : 1527 (1970).
Petrzilka, T. and Sikemeier, C.: "Uber Inlialtsstoffe des Hashish II," Helvitia Clinica Acta, 50: 1410-1419 (1967).
Petrzilka, T. and Sikemeier, C.: "Uber Inlialsstoffe des Hashish III," Helvitia Chinica Acta, 50: 2111-2113 (1967).
Phillips, R. N., Turk, R. F. and Forney, R. B.: "Acute Toxicity of A' Tetrahydrocannabinol in Rats and Mice," Proceedings of Society for Experimental Biology and Medicine, 136(l) :260-263 (1971).
Phillips, R., Turk, R., Manno, J., Jain, N. and Forney R.: "Seasonal Variations in Cannabinolic Content of Indiana Marihuana," Journal of Forensic Sciences, 15(2) 191-200 (1970).
Phillips, R. N., Brown, D. J., Martz, R. C., Hubbard, J. D. and Forney, R. B.: "Subacute Toxicity of WaterSuspended (-)Delta-9-Tetrahydrocannabinol in Rats, Toxicology and Applied Pharmacology, 19(2) : 414 (1971).
Pillard, R. C.: "Marihuana," New England Journal of Medicine, 283(6) : 294-303 (1970).
Pirch, J. H., Colin. R. A., Barnes, P. R. and Barrett, E. S.: "Tolerance to EEG and Behavioral Effects of Marihuana in Rats," The Pharmacologist, 13(2) : 246 (1971).
Pivik, T., Zareone, V. Hollister, L. E. & Dement, W.: "The Effects of Hallucinogenic Agents on Sleep," Paychophysiology, 6(2) : 261 (1969).
Podolsky, S., Pattavina, C., and Amaral. M.: Effects of Marihuana on Glucose Tolerance Test (G.T.T.)," Annals of the New York Academy of Science, 191: 54-6 (1971).
Porot, A: "Le Cannabisme," Annales Medico-Psychologique8z 1(1) : 1-24 (1942).
Powelson, H. D., Personal Communication, Chief Psychiatrist, University of California, Berkeley, "Clinical Notes on the Use of Marihuana," (1970).
Prince, R., Greenfield, R. and Marriott: "Ganja: The Benevolent Alternative? Observations on Use of Cannabis and Alcohol in Jamaica," Mental Health Institute, Montreal, unpublished manuscript 1970).
Reales-Orozeo, et al.: "Aspectos Generales de la Intoxicacion Por Marihuana y Sus Manifestaciones Psiquiatricas en Barranquilla," Revista de Medicina Legal de Colombia, 13: 142-148 (1953).
Renault, P. P., Schuster, C. R., Heinrich, R. and Freedman, D. X.:"Marihuana: Standardized Smoke Administration and Dose Effect Curves on Heart Rate in Humans," Science, 174 (4009) : 589-591 (1971).
Rickles, W. H., Kales, A., and Hanley, J.: "Effects of Marihuana on Evoked Heart Rate and Skin Conductance Responses," Presented at Society for Psychophysiological Research Meeting, New Orleans (November 22, 1970).
Rickles, W. H., Kales, A., and Hanley, J.: "Psychophysiology of Marihuana," Presented to Langley Porter Nueropsychiatrie Institute, San Francisco (May 1970).
Robins, L. N. and Murphy, G. E.: "Drug Use in a Normal Population of Young Negro Men," American Journal of Public Health, 57 (9) :1580-1596 (1967).
Rodin, E. and Domino, E. F.: "Effects of Acute Marihuana Smoking in the Electroencephalograms," Electroencephalography and Clinical Ncurophysiology, 29: 321 (1970).
Rodin, E., Domino, E. P., and Porzak, J. P.: "The Marihuana-Induced 'Social High'-Neurological and Electroencephalographic Concomitants," Journal of the American Medical Association, 213 (8) : 1300-1302 (1970).
Roth, W. T., Galanter, M., Weingartner, H., Vaughan, T. B., and Wyatt, R. J.: "The Effect of Marihuana and Synthetic delta-9-THC on Auditory Evoked Response and Background EEG in Humans," Laboratory of Clinical Pharmacology, National Institute of Mental Health, Bethesda, Maryland (unpublished 1972).
Rubin, V. and Comitas, L.: "A Study of the Effects of Chronic Ganja Smoking in Jamaica," Research Institute for the Study of 'Man, New York, in preparation for tration and Dose Effect Curves on Heart Rate in Huthe National Institute of Mental Health, Contract No. 11811 42-70-77 (1972).
Sagone, L., Laurence, T. and Balcerzak, S. P.: "SmokingA Cause of 'Spurious' Polyeythemia," Blood: The Journal of Hematology, XXXVIII (6) : 118 (1971).
Scher, J. M.: "The Marihuana Habit," Journal of the American Medical Association, 214 (6) : 1120 (1970). Schuster, C. R. and Renault, P. F.: Personal Communication, Department of Psychiatry, School of Medicine University of Chicago, January 1972.
Schwartz, C. J.: "Toward a Medical Understanding of Marihuana," Canadian Psychiatric Association Journal 14: 591400 (1969).
Secretary of Health, Education, and Welfare: "Marihuana and Health," A Report to the Congress (January 1971).
Secretary of Health, Education, and Welfare: "Marihuana and Health," A Report to the Congress (February 1972).
Shean, G. D. and Fetchtman. P.: "Purpose in Life Scores of Student Marihuana Users," Journal of Clinical Psychology, 27 (1) :112-113 (1971).
Sigg, B. W.: "Le Cannabisme Chronique. Fruit (le Sons Development et du Capitalisnie: Etude Socio-Econo que et psycho-pathologique," Algiers (1963).
Siler, J. P., Sheep, W. L., Bates, L. B., Clark, G. F., Cook, G. W. and Smith, W. A.: "Marihuana Smoking in Panama," The Military Surgeon, 73 (5) : 269-280 (1933).
Silva, M. T. A., Carlini, E. A., Claussen, U. and Korte, F.: "Lack of Cross-Tolerance in Rate Among (-) Delta 9-TransTetrahydrocannabinol (Delta 9-THC), Cannabis Extract, Mescaline and Lysergic Acid Diethylamide (LSD-25)," Psychopharmacologia, 13: 332-340 (1968).
Sim, V. M. and Tucker, L. A.: "Summary Report on EA 1476 and EA 2233," U.S. Army Chemical Research and Development Laboratories, Special Publication 1-44 (1963).
Simmons, J. L. and Winograd, B.: It's Happening: A Portrait of the Youth Scene Today, Santa Barbara: MarcLaird Publications (1966).
Smith, D. E.: "Acute and Chronic Toxicity of Marihuana," Journal of Psychedelic Drugs, 2: 37-41 (1968).
Smith, D. E. and Mehl, C.: The New Social Drug, Englewood Cliffs: Prentice-Hall, Inc. (1970), pp. 63-77.
Sonnenreich, C., and Goes, J. P.: "Marihuana and Mental Disturbances," Neurobiologia, 25: 69-91 (1962).
Soueif, M. I.: "Hashish Consumption in Egypt with Special Reference to Psychological Aspects," UN Bulletin on Narcotics, 19 (2) : 1-12 (1967).
Spencer, J. D.: "Cannabis Induced Psychosis," British Journal of Addiction, 651: 369-372 (1970).
Sterne, J. and Ducastaing, C.: "Les Arterites du Cannabis Indica," Archives des Maladies du Coeur et des Vais8eaux, 53: 143-147 (1960).
Stringaris, M. G.: "Zur Klink der Hashchischpsychosen (Nach Studien in Griechenland)," Archiv fur Psychiatric and Nervenkranhheiten, 100 (4) : 522-532 (1933). Suchman, E. A.: "The 'hang-Loose' Ethic and the Spirit of Drug Use," Journal of Health and Social Behavior, 9: 146-155 (1968).
Talbott, J. A. - "Pot Reactions," USARMY Medical Bulletin, 40-41 (1968).
Talbot, J. A., and Teague, J. W.: "Marihuana, Psychosis: Acute Toxic Psychosis Associated With the Use of Cannabis Derivatives," Journal of the American Medical Association, 210 (2) :299--302 (1969).
Tart, C. T.: "Marihuana Intoxication, Common Experiences," Nature, 226 (5247) : 701-704 (1970). Tart, C. T.: "Marihuana Intoxication: Reported Effects On Sleep and Dreams," Presented Association for Psychophysiological Study of Sleep, Santa Fe (1970). Tart, C. T.: On Being Stoned, Palo Alto: Science and Behavioral Books (1971).
Tennant, F. S., Preble, It., Prendergast, T. J. and Ventry, P.: "Medical Manifestations Associated With Hashish," Journal of the American Medical Association, 216 (12) 1965-1969 (1971).
Thompson, G. R., Rosencrantz, 11. and Brande, M. C.: "Neurotoxicity of the Cannabinoids in Chronically Treated Rats and Monkeys," The Pharmacologist, 13 (2) : 296 (1971).
Thompson, G. R., Schaeppi, U. T., Rosencrantz, H. and Brande, Al. C.: "Acute Oral Toxicity of Cannabinoids in Various Species," Toxicology and Applied Pharmacology, 19 (2) : 413 (1971).
Thompson, G. R., Schaeppi, U. IT., Rosencrantz, H. N., Hagopian, M, Mason, M. M., Fleishman, R. W., and Hamniann, C. G.: "Determine, Toxicity of delta 8 and delta 9 Tetrahydrocannabinol and Marihuana Extract," Mason Research Institute, Worcester, Mass., Reports IXIX to the National Institute of Mental Health Contract #HSM 42-70-95 (June 1970-June 1971), #HSM 42-71-79 (June 1971-Jan. 1972).
Tinklenberg, J. R., Melges, F. T., Hollister, L. E., and Gillespie, H. K.: "Marihuana and Immediate Memory,"
Nature, 226 (5251) : 1171 1172 (June 1970).
Truitt, E. B.: "Biologic Disposition of Tetrahydrocannabinols," Pharmacological Review, 23 (4) : 273-278 (1971).
Truitt, E., Mitchell, R., Foltz, R., Fentiman, A., Kinzer, G., Grotta, II., and Leighty, E.: "Bioanalytical 'Studies of Cannabis Smoking," Report to the National Institute of Mental Health, Contract Number P11-43-68-1338, Battelle Memorial Institute, Columbus, Ohio (1970).
Ungerleider, J. T.: "Letter to the Editor," American Journal of Psychiatry, 125: 1448 (1969).
Ungerleider, J. T., Fischer, D. D., Goldsmith, R. S., Fuller, M., and Forgy, E.: "A Statistical Survey of Adverse Reactions to LSD in Los Angeles County," American Journal of Psychiatry, 125 (3) : 352-357 (1968).
United Nations Economic and Social Council: "A Programme of Studies of the Plan and Its Products, Survey of the Cannabis Situation in India," U.N. Document No. E/CN.7/286, Addendum 12 (March 1957).
Volavka, J., Dornbush, R., Feldstein, S., Clare, G., Zaks, A., Fink, M., and Freedman, A. M.: "Marihuana, EEG and Behavior," Annals of the New York Academy of Science, 191: 206-215 (1971).
Vree, T. B., Breinier, 1). D., Van Ginneken, C. A. M. and Van Rossum, J. M.: "Identification of the Methyl and Propyl Homologues of CBD, THC, CBN in Hashish by a New Method of Combined Gas Chromatography-mass Spectrometry," Acta Pharmaceutica Suecica, 8: 683684 (1971).
Waldman, M. M.: "Marihuana Bronchitis," Journal of the American Medical Association, 211: 501 (1970).
Wall, M. E.: "The InVitro and InVivo Metabolism of Tetrahydrocannabinol (THC)," Annals of the New York Academy of Science, 191: 23-39 (1971).
Wall, M. E., -Brine, -1). R., J-1rine, G. A. Pitt, C. G., Emudenthal, R. 1. and Christensen, H. D.: "Isolation, Structure, and Biological Activity of Several Metabolites of A' Tetrahydrocannabinol," Journal of the American Chemical Society, 92 (11) : 3466-3468 (1970).
Wall, Al. E., Brine, D., Perez-Reyes, Al. and Lipton, M.: "Studies on the InVitro and InVivo Metabolism of A' Tetrahydrocannabinol," Acta Pharmaceutica Suecica, 8: 702 (1971).
Waller, C. W.: "The Chemistry of Marihuana," Proceedings of the Western Pharmacology Society, 14: 1-3 (1971).
Walters, P. A., Goethals, G. W. and Pope, H. G.: "Drug Use and Life Style Among 500 College Undergraduates" Archives of General Psychiatry, 26: 92-96 (1972).
Walton, R. P.: Marihuana, America's New Drug Problem, Philadelphia: J. B. Lippincott Co. (1938).
Warnock, J.: "Insanity from Hasheesh," Journal of Mental Sciences, 49: 96-110 (1903).
Waskow, 1. E., Olsson, J. E., Salzman, C. and Katz, Al. M.: "Psychological Effects of Tetraliydrocannabinol," Archives of General Psychiatry, 22 (2): 97-107 (1970).
Watt, J. M.: "Dagga in South Africa," UN Bulletin on Narcotics, 13 (3) : 9-14 (1961).
Watt, J. M. and Breyer-Brandwijk, M. B.: The Forensic and Sociological Aspects of the Dagga Problem in South Africa," South African Medical Journal, 10: 573-579 (1936).
Weil, A. T.: "Adverse Reactions to Marihuana. Classification and Suggested Treatment," New England Journal of Medicine, 282 (18) : 997-1000 (1970).
Weil, A. T.: Testimony before National Commission on Marihuana and Drug Abuse, Washington, D.C. (May 1971).
Weil, A. T., and Zinberg, N. E.: "Acute Effects of Marihuana on Speech," Nature, 222: 434-437 (1969). Weil, A. T., Zinberg, N. E. and Nelsen, J. ',M.: "Clinical and Psychological Effects of marihuana in Alan," Science, 162: 1234-1242 (1968).
Weiss, J. L.: Personal Communication, Staff Fellow, National Institute of Mental Health, Laboratory of Clinical Science, Bethesda, Maryland, August 1, 1971. Weiss, S.: "A General Picture of Charas Habit in Afghanistan," Report from Kabul University Medical School (July 1971).
White, R. B., Goolishian, H., and Barratt, E. S.: "Dilemmas Encountered by the Marihuana Researcher," Presented 46th Annual Conference of the Central Neuropsychiatric Association, Galveston (October 1970).
Wikler, A.: "Clinical and Social Aspects of Marihuana Intoxication," Archives of General Psychiatry, 23: 320-325 (1970).
Wikler, A., and Lloyd, B. J.: "Effect of Smoking Marihuana Cigarettes on Cortical Electrical Activity," Federation Proceedings, 4: 141-142 (1945).
William,,;, E. G., Himmelsbach, C. K., Wikler, A., Ruble, D. C., and Lloyd, B.N.: "Studies on Marihuana and Pyrahexyl Compound," Public Health Reports, 61 (29) 1059-1083 (1946).
Winick, C.: "Use of Drugs by Jazz Musicians," Social Problems, 7: 240-253 (1960).
Wurmser, L., Levin, L., and Lewis, A.: "Chronic Paranoid Symptoms and Thought
Disorders in Users of Marihuana and LSD as Observed in Psychotherapy," Bulletin,
Problems on Drug Dependence, 31: 6154-6177 (1969).
Contents | Feedback | Search | DRCNet Home Page | Join DRCNet
DRCNet Library | Schaffer Library | Major Studies
Marihuana, A Signal of Misunderstanding